These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 19433385)

  • 41. Bone loss in patients with breast cancer receiving aromatase inhibitors and associated treatment strategies.
    Coleman RE; Body JJ; Gralow JR; Lipton A
    Cancer Treat Rev; 2008; 34 Suppl 1():S31-42. PubMed ID: 18486346
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bisphosphonates and bone turnover in premenopausal women receiving adjuvant chemotherapy.
    Paterson A; Baker T
    J Clin Oncol; 2009 Mar; 27(7):1005-6. PubMed ID: 19171701
    [No Abstract]   [Full Text] [Related]  

  • 43. Sowing the soil for cure? Results of the ABCSG-12 trial open a new chapter in the evolving adjuvant bisphosphonate story in early breast cancer.
    Bedard PL; Body JJ; Piccart-Gebhart MJ
    J Clin Oncol; 2009 Sep; 27(25):4043-6. PubMed ID: 19652062
    [No Abstract]   [Full Text] [Related]  

  • 44. [Antitumour effects of bisphosphonates in breast cancer].
    van de Ven S; Kroep JR; Hamdy NA; Sleeboom HP; Nortier HW
    Ned Tijdschr Geneeskd; 2010; 154():A1951. PubMed ID: 21083955
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
    Bundred NJ; Campbell ID; Davidson N; DeBoer RH; Eidtmann H; Monnier A; Neven P; von Minckwitz G; Miller JC; Schenk NL; Coleman RE
    Cancer; 2008 Mar; 112(5):1001-10. PubMed ID: 18205185
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Zoledronic acid prevents cancer treatment-induced bone loss.
    Oncology (Williston Park); 2005 Mar; 19(3):390. PubMed ID: 15828553
    [No Abstract]   [Full Text] [Related]  

  • 47. Unexpected AZURE results lead to rethink for Zometa(®).
    Robinson F
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):329. PubMed ID: 21417848
    [No Abstract]   [Full Text] [Related]  

  • 48. [New development in breast cancer therapy. III. Zoledronic acid and anti-tumor immunity in breast cancer].
    Sugie T; Tanaka Y; Toi M
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2555-9. PubMed ID: 20104681
    [No Abstract]   [Full Text] [Related]  

  • 49. Potential role of bone-directed therapy on the superiority of aromatase inhibitors over tamoxifen.
    Oyan B
    Med Hypotheses; 2011 Dec; 77(6):1028-30. PubMed ID: 21930348
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Resolution of bone lysis in Langerhans cell histiocytosis by bisphosphonate therapy.
    Tsuda H; Yamasaki H; Tsuji T
    Br J Haematol; 2011 Aug; 154(3):287. PubMed ID: 21595647
    [No Abstract]   [Full Text] [Related]  

  • 51. Emerging bone health issues in women with breast cancer in Hawai'i.
    Carney JF; Davis J
    Hawaii Med J; 2007 Jun; 66(6):164-6. PubMed ID: 17621865
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bisphosphonates and bone diseases: past, present and future.
    Heymann D
    Curr Pharm Des; 2010; 16(27):2948-9. PubMed ID: 20722613
    [No Abstract]   [Full Text] [Related]  

  • 53. Optimal use of bisphosphonates in patients with multiple myeloma.
    Terpos E; Roodman GD; Dimopoulos MA
    Blood; 2013 Apr; 121(17):3325-8. PubMed ID: 23407550
    [No Abstract]   [Full Text] [Related]  

  • 54. Bisphosphonates, bone, and breast cancer recurrence.
    Brufsky A; Mathew A
    Lancet; 2015 Oct; 386(10001):1319-1320. PubMed ID: 26211825
    [No Abstract]   [Full Text] [Related]  

  • 55. Herbert Andre Fleisch, MD.
    Martin TJ; Bonjour JP; Russell RG
    J Bone Miner Res; 2007 Nov; 22(11):1651-3. PubMed ID: 17931098
    [No Abstract]   [Full Text] [Related]  

  • 56. [Bisphosphonates].
    Sabourin G
    Perspect Infirm; 2016; 13(1):71. PubMed ID: 26998546
    [No Abstract]   [Full Text] [Related]  

  • 57. Role of oestrogen in the development of joint symptoms?
    Tan AL; Emery P
    Lancet Oncol; 2008 Sep; 9(9):817-8. PubMed ID: 18760239
    [No Abstract]   [Full Text] [Related]  

  • 58. Supportive care in oncology.
    Coleman RE
    Support Care Cancer; 2005 Dec; 13(12):959-60. PubMed ID: 16133072
    [No Abstract]   [Full Text] [Related]  

  • 59. Bone Disease in Myeloma: The Claws of CRAB.
    Fonseca R; Jain T
    Clin Cancer Res; 2016 Mar; 22(6):1301-3. PubMed ID: 26792259
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Bisphosphonates: beyond prevention of bone metastases.
    Rennert G
    J Natl Cancer Inst; 2011 Dec; 103(23):1728-9. PubMed ID: 22021669
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.